Oncothyreon Stock Surges on Partner’s Renewed Bet in Lung Cancer – Xconomy

by lowes1 on September 26, 2013

Oncothyreon Stock Surges on Partner's Renewed Bet in Lung Cancer
Seattle-based Oncothyreon (NASDAQ: ONTY) was written off by a lot of investors last year when a cancer immunotherapy it developed failed in a pivotal clinical trial run by one of its partners. Today, the company bounced back as its partner, Merck KGaA

and more »

View full post on lung cancer – Google News

Leave a Comment

Previous post:

Next post: